14 Sep
2021

$8 billion Sobi takeover shows orphan drug IP assets are in high demand

The multi-billion dollar acquisition of Swedish specialist orphan drug business Sobi is the latest example of investors’ interest in rare disease innovations

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth